Industry Active Role In Guidance Development Urged By Wyeth's Burlington
Executive Summary
Regulated industry should take a more aggressive approach to writing guidances, Wyeth-Ayerst Senior VP-Global Regulatory Affairs Bruce Burlington, PhD, told a Parenteral Drugs Association/FDA joint conference Sept. 29 in Bethesda, Md.
You may also be interested in...
FDA Should Get Industry Input Before Issuing Draft Guidances - PhRMA
FDA should get input from industry before the release of draft guidances, the Pharmaceutical Research & Manufacturers of America suggests in comments to FDA on the implementation of good guidance practice provisions included in the FDA Modernization Act.
PhRMA Quality Of LIfe Measurement Recommendations Expected in July
The Pharmaceutical Research & Manufacturers of America Health Outcomes Working Group is compiling health-related quality of life measurement recommendations in a report for industry.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011